The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity

Journal of Nutritional Biochemistry

Volumn 24, Issue 12, 2013, Pages 2003-2015

  Frigolet, Maria E ^a   Torres, Nimbe ^b   Tovar, Armando R ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Adipocyte; Adipose tissue; Diabetes; Diet; Hypertension; Renin angiotensin system

Indexed keywords

ADIPOCYTOKINE; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CONJUGATED LINOLEIC ACID; FRUCTOSE; INSULIN; IRBESARTAN; LIPID; OLMESARTAN; OMEGA 3 FATTY ACID; POLYUNSATURATED FATTY ACID; REACTIVE OXYGEN METABOLITE; SOYBEAN PROTEIN; TELMISARTAN; VALSARTAN;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; CYTOKINE RELEASE; DIABETES MELLITUS; DIET; ENVIRONMENTAL FACTOR; FAT INTAKE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LABORATORY; LIPID METABOLISM; LIPOGENESIS; MACROPHAGE; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; NUTRIENT; OBESITY; PROTEIN INTAKE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ADIPOCYTE; ADIPOSE TISSUE; DIABETES; DIET; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

ADIPOCYTES; ADIPOGENESIS; ADIPOKINES; ADIPOSE TISSUE; ANIMALS; DIET; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 84887614586     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2013.07.002     Document Type: Review

References (230)

1. Phillips MI, Schmidt-Ott KM. The Discovery of Renin 100 Years Ago. News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society. 1999;14:271-4.
2. Naruse K., Inagami T., Celio M.R., Workman R.J., Takii Y. Immunohistochemical evidence that angiotensins I and II are formed by intracellular mechanism in juxtaglomerular cells. Hypertension 1982, 4:70-74.
3. Persson P.B. Renin: origin, secretion and synthesis. J Physiol 2003, 552:667-671.
4. Nguyen A., Cat D., Touyz R.M. A new look at the renin-angiotensin system - focusing on the vascular system. Peptides 2011, 32:2141-2150.
5. Beneteau-Burnat B., Baudin B. Angiotensin-converting enzyme: clinical applications and laboratory investigations on serum and other biological fluids. Crit Rev Clin Lab Sci 1991, 28:337-356.
6. Kuoppala A., Lindstedt K.A., Saarinen J., Kovanen P.T., Kokkonen J.O. Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma. Am J Physiol Heart Circ Physiol 2000, 278:H1069-H1074.
7. Higuchi S., Ohtsu H., Suzuki H., Shirai H., Frank G.D., Eguchi S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 2007, 112:417-428.
8. Lemarié C.A., Schiffrin E.L. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2010, 11:19-31.
9. Savoia C., Touyz R.M., Endemann D.H., Pu Q., Ko E.A., De Ciuceis C., et al. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension 2006, 48:271-277.
10. Horiuchi M., Lehtonen J.Y., Daviet L. Signaling mechanism of the AT2 angiotensin II receptor: crosstalk between AT1 and AT2 receptors in cell growth. Trends Endocrinol Metab 1999, 10:391-396.
11. Putnam K., Shoemaker R., Yiannikouris F., Cassis L.A. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012, 302:H1219-H1230.
12. De Mello W.C., Frohlich E.D. On the local cardiac renin angiotensin system. Basic and clinical implications. Peptides 2011, 32:1774-1779.
13. Kumar R., Thomas C.M., Yong Q.C., Chen W., Baker K.M. The intracrine renin-angiotensin system. Clin Sci (Lond) 2012, 123:273-284.
14. Balcells E., Meng Q.C., Johnson W.H., Oparil S., Dell'Italia L.J. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997, 273:H1769-H1774.
15. Urata H., Boehm K.D., Philip A., Kinoshita A., Gabrovsek J., Bumpus F.M., et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993, 91:1269-1281.
16. Johnston A.P., Baker J., De Lisio M., Parise G. Skeletal muscle myoblasts possess a stretch-responsive local angiotensin signalling system. J Renin Angiotensin Aldosterone Syst 2011, 12:75-84.
17. Campbell D.J., Habener J.F. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest 1986, 78:31-39.
18. Deschepper C.F., Mellon S.H., Cumin F., Baxter J.D., Ganong W.F. Analysis by immunocytochemistry and in situ hybridization of renin and its mRNA in kidney, testis, adrenal, and pituitary of the rat. Proc Natl Acad Sci USA 1986, 83:7552-7556.
19. Ganten D., Minnich J.L., Granger P., Hayduk K., Brecht H.M., Barbeau A., et al. Angiotensin-forming enzyme in brain tissue. Science 1971, 173:64-65.
20. Hellmann W., Suzuki F., Ohkubo H., Nakanishi S., Ludwig G., Ganten D. Angiotensinogen gene expression in extrahepatic rat tissues: application of a solution hybridization assay. Naunyn Schmiedebergs Arch Pharmacol 1988, 338:327-331.
21. Bays H.E., Gonzalez-Campoy J.M., Bray G.A., Kitabchi A.E., Bergman D.A., Schorr A.B., et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008, 6:343-368.
22. Janke J., Engeli S., Gorzelniak K., Luft F.C., Sharma A.M. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002, 51:1699-1707.
23. Engeli S., Negrel R., Sharma A.M. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000, 35:1270-1277.
24. Cassis L.A. Fat cell metabolism: insulin, fatty acids, and renin. Curr Hypertens Rep 2000, 2:132-138.
25. Umemura S., Nyui N., Tamura K., Hibi K., Yamaguchi S., Nakamaru M., et al. Plasma angiotensinogen concentrations in obese patients. Am J Hypertens 1997, 10:629-633.
26. Van Harmelen V., Ariapart P., Hoffstedt J., Lundkvist I., Bringman S., Arner P. Increased adipose angiotensinogen gene expression in human obesity. Obes Res 2000, 8:337-341.
27. Giacchetti G., Faloia E., Sardu C., Camilloni M.A., Mariniello B., Gatti C., et al. Gene expression of angiotensinogen in adipose tissue of obese patients. Int J Obes 2000, 24(Suppl 2):S142-S143.
28. Jonsson J.R., Game P.A., Head R.J., Frewin D.B. The expression and localisation of the angiotensin-converting enzyme mRNA in human adipose tissue. Blood Press 1994, 3:72-75.
29. Fowler J.D., Johnson N.D., Haroldson T.A., Brintnall J.A., Herrera J.E., Katz S.A., et al. Regulated renin release from 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2009, 296:E1383-E1391.
30. Saye J.A., Ragsdale N.V., Carey R.M., Peach M.J. Localization of angiotensin peptide-forming enzymes of 3T3-F442A adipocytes. Am J Physiol 1993, 264:C1570-C1576.
31. Shenoy U., Cassis L. Characterization of renin activity in brown adipose tissue. Am J Physiol 1997, 272:C989-C999.
32. Weiland F., Verspohl E.J. Local formation of angiotensin peptides with paracrine activity by adipocytes. J Pept Sci 2009, 15:767-776.
33. Achard V., Boullu-Ciocca S., Desbriere R., Nguyen G., Grino M. Renin receptor expression in human adipose tissue. Am J Physiol Regul Integr Comp Physiol 2007, 292:R274-R282.
34. Takahashi K., Yamamoto H., Hirose T., Hiraishi K., Shoji I., Shibasaki A., et al. Expression of (pro)renin receptor in human kidneys with end-stage kidney disease due to diabetic nephropathy. Peptides 2010, 31:1405-1408.
35. Archard V., Tassistro V., Boullu-Giocca S., Grino M. Expression and nutritional regulation of the (pro)renin receptor in rat visceral adipose tissue. J Endocrinol Invest 2011, 34:840-846.
36. Karlsson C., Lindell K., Ottosson M., Sjostrom L., Carlsson B., Carlsson L.M. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998, 83:3925-3929.
37. Engeli S., Gorzelniak K., Kreutz R., Runkel N., Distler A., Sharma A.M. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 1999, 17:555-560.
38. Kalupahana N.S., Moustaid-Moussa N. The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obes Rev 2012, 13:136-149.
39. Taleb S., Cancello R., Clement K., Lacasa D. Cathepsin s promotes human preadipocyte differentiation: possible involvement of fibronectin degradation. Endocrinology 2006, 147:4950-4959.
40. Xiao Y., Junfeng H., Tianhong L., Lu W., Shulin C., Yu Z., et al. Cathepsin K in adipocyte differentiation and its potential role in the pathogenesis of obesity. J Clin Endocrinol Metab 2006, 91:4520-4527.
41. Yang M., Zhang Y., Pan J., Sun J., Liu J., Libby P., et al. Cathepsin L activity controls adipogenesis and glucose tolerance. Nat Cell Biol 2007, 9:970-977.
42. Crandall D.L., Herzlinger H.E., Saunders B.D., Zolotor R.C., Feliciano L., Cervoni P. Identification and characterization of angiotensin II receptors in rat epididymal adipocyte membranes. Metabolism 1993, 42:511-515.
43. Crandall D.L., Armellino D.C., Busler D.E., McHendry-Rinde B., Kral J.G. Angiotensin II receptors in human preadipocytes: role in cell cycle regulation. Endocrinology 1999, 140:154-158.
44. Crandall D.L., Herzlinger H.E., Saunders B.D., Armellino D.C., Kral J.G. Distribution of angiotensin II receptors in rat and human adipocytes. J Lipid Res 1994, 35:1378-1385.
45. Gorzelniak K., Engeli S., Janke J., Luft F.C., Sharma A.M. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 2002, 20:965-973.
46. Jones B.H., Standridge M.K., Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 1997, 138:1512-1519.
47. Mallow H., Trindl A., Loffler G. Production of angiotensin II receptors type one (AT1) and type two (AT2) during the differentiation of 3T3-L1 preadipocytes. Horm Metab Res 2000, 32:500-503.
48. Juan C.C., Chien Y., Wu L.Y., Yang W.M., Chang C.L., Lai Y.H., et al. Angiotensin II enhances insulin sensitivity in vitro and in vivo. Endocrinology 2005, 146:2246-2254.
49. Morris K.L., Zemel M.B. Effect of dietary carbohydrate source on the development of obesity in agouti transgenic mice. Obes Res 2005, 13:21-35.
50. Kim S., Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000, 52:11-34.
51. Weiland F., Verspohl E.J. Variety of angiotensin receptors in 3T3-L1 preadipose cells and differentiated adipocytes. Horm Metab Res 2008, 40:760-766.
52. Benter I.F., Yousif M.H., Cojocel C., Al-Maghrebi M., Diz D.I. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 2007, 292:H666-H672.
53. Liu C., Lv X.H., Li H.X., Cao X., Zhang F., Wang L., et al. Angiotensin-(1-7) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes. Acta Diabetol 2012, 49:291-299.
54. Mario E.G., Santos S.H., Ferreira A.V., Bader M., Santos R.A., Botion L.M. Angiotensin-(1-7) Mas-receptor deficiency decreases peroxisome proliferator-activated receptor gamma expression in adipocytes. Peptides 2012, 33:174-177.
55. Caron A.Z., Arguin G., Guillemette G. Angiotensin IV interacts with a juxtamembrane site on AT(4)/IRAP suggesting an allosteric mechanism of enzyme modulation. Regul Pept 2003, 113:9-15.
56. Keller S.R., Davis A.C., Clairmont K.B. Mice deficient in the insulin-regulated membrane aminopeptidase show substantial decreases in glucose transporter GLUT4 levels but maintain normal glucose homeostasis. J Biol Chem 2002, 277:17677-17686.
57. Keller S.R., Scott H.M., Mastick C.C., Aebersold R., Lienhard G.E. Cloning and characterization of a novel insulin-regulated membrane aminopeptidase from Glut4 vesicles. J Biol Chem 1995, 270:23612-23618.
58. Marcus Y., Shefer G., Stern N. Adipose tissue renin-angiotensin -aldosterone system (RAAS) and progression of insulin resistance. Mol Cell Endocrinol 2013, 378:1-14.
59. Cassis L.A., Police S.B., Yiannikouris F., Thatcher S.E. Local adipose tissue renin-angiotensin system. Curr Hypertens Rep 2008, 10:93-98.
60. Faloia E., Gatti C., Camilloni M.A., Mariniello B., Sardu C., Garrapa G.G., et al. Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects. J Endocrinol Invest 2002, 25:309-314.
61. Massiera F., Bloch-Faure M., Ceiler D., Murakami K., Fukamizu A., Gasc J.M., et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001, 15:2727-2729.
62. Yasue S., Masuzaki H., Okada S., Ishii T., Kozuka C., Tanaka T., et al. Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy. Am J Hypertens 2010, 23:425-431.
63. Galvez-Prieto B., Bolbrinker J., Stucchi P., de Las Heras A.I., Merino B., Arribas S., et al. Comparative expression analysis of the renin-angiotensin system components between white and brown perivascular adipose tissue. J Endocrinol 2008, 197:55-64.
64. Greenstein A.S., Khavandi K., Withers S.B., Sonoyama K., Clancy O., Jeziorska M., et al. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 2009, 119:1661-1670.
65. Lu C., Zhao A.X., Gao Y.J., Lee R.M. Modulation of vein function by perivascular adipose tissue. Eur J Pharmacol 2011, 657:111-116.
66. Oliver J.A., Sciacca R.R. Local generation of angiotensin II as a mechanism of regulation of peripheral vascular tone in the rat. J Clin Invest 1984, 74:1247-1251.
67. Giacchetti G., Faloia E., Mariniello B., Sardu C., Gatti C., Camilloni M.A., et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 2002, 15:381-388.
68. Anderson P.J., Chan J.C., Chan Y.L., Tomlinson B., Young R.P., Lee Z.S., et al. Visceral fat and cardiovascular risk factors in Chinese NIDDM patients. Diabetes Care 1997, 20:1854-1858.
69. Peiris A.N., Sothmann M.S., Hoffmann R.G., Hennes M.I., Wilson C.R., Gustafson A.B., et al. Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med 1989, 110:867-872.
70. Hajer G.R., van Haeften T.W., Visseren F.L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008, 29:2959-2971.
71. Pausova Z. From big fat cells to high blood pressure: a pathway to obesity-associated hypertension. Curr Opin Nephrol Hypertens 2006, 15:173-178.
72. Iwai M., Horiuchi M. Role of renin-angiotensin system in adipose tissue dysfunction. Hypertens Res 2009, 32:425-427.
73. Boschmann M., Ringel J., Klaus S., Sharma A.M. Metabolic and hemodynamic response of adipose tissue to angiotensin II. Obes Res 2001, 9:486-491.
74. Kouyama R., Suganami T., Nishida J., Tanaka M., Toyoda T., Kiso M., et al. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 2005, 146:3481-3489.
75. Iwai M., Chen R., Imura Y., Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007, 20:579-586.
76. Henriksen E.J., Jacob S., Kinnick T.R., Teachey M.K., Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001, 38:884-890.
77. Munoz M.C., Giani J.F., Dominici F.P., Turyn D., Toblli J.E. Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. J Hypertens 2009, 27:2409-2420.
78. Henriksen E.J., Jacob S. Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism 1995, 44:267-272.
79. Jacob S., Henriksen E.J., Fogt D.L., Dietze G.J. Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle. Metabolism 1996, 45:535-541.
80. Jauch K.W., Hartl W., Guenther B., Wicklmayr M., Rett K., Dietze G. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1987, 17:448-454.
81. Paolisso G., Gambardella A., Verza M., D'Amore A., Sgambato S., Varricchio M. ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 1992, 6:175-179.
82. Pollare T. Insulin sensitivity and blood lipids during antihypertensive treatment with special reference to ACE inhibition. J Diabet Complications 1990, 4:75-78.
83. Torlone E., Britta M., Rambotti A.M., Perriello G., Santeusanio F., Brunetti P., et al. Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes. Diabetes Care 1993, 16:1347-1355.
84. Vuorinen-Markkola H., Yki-Jarvinen H. Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism 1995, 44:85-89.
85. Lastra G., Habibi J., Whaley-Connell A.T., Manrique C., Hayden M.R., Rehmer J., et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009, 150:2561-2568.
86. Marchionne E.M., Diamond-Stanic M.K., Prasonnarong M., Henriksen E.J. Chronic renin inhibition with aliskiren improves glucose tolerance, insulin sensitivity, and skeletal muscle glucose transport activity in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2012, 302:R137-R142.
87. Folli F., Kahn C.R., Hansen H., Bouchie J.L., Feener E.P. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997, 100:2158-2169.
88. Velloso L.A., Folli F., Sun X.J., White M.F., Saad M.J., Kahn C.R. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 1996, 93:12490-12495.
89. Takayama S., White M.F., Kahn C.R. Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity. J Biol Chem 1988, 263:3440-3447.
90. Tanti J.F., Gremeaux T., van Obberghen E., Le Marchand-Brustel Y. Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. J Biol Chem 1994, 269:6051-6057.
91. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
92. Zohn I.E., Yu H., Li X., Cox A.D., Earp H.S. Angiotensin II stimulates calcium-dependent activation of c-Jun N-terminal kinase. Mol Cell Biol 1995, 15:6160-6168.
93. Chang H.H., Tsai P.H., Liu C.W., Ku H.C., Kao C.C., Kao Y.H. Cycloheximide stimulates suppressor of cytokine signaling-3 gene expression in 3T3-L1 adipocytes via the extracellular signal-regulated kinase pathway. Toxicol Lett 2013, 217:42-49.
94. Emanuelli B., Peraldi P., Filloux C., Chavey C., Freidinger K., Hilton D.J., et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 2001, 276:47944-47949.
95. Emanuelli B., Peraldi P., Filloux C., Sawka-Verhelle D., Hilton D., Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 2000, 275:15985-15991.
96. Ueki K., Kondo T., Kahn C.R. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004, 24:5434-5446.
97. Hilton D.J., Richardson R.T., Alexander W.S., Viney E.M., Willson T.A., Sprigg N.S., et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA 1998, 95:114-119.
98. Velloso L.A., Folli F., Perego L., Saad M.J. The multi-faceted cross-talk between the insulin and angiotensin II signaling systems. Diabetes Metab Res Rev 2006, 22:98-107.
99. Limor R., Moataz U., Knol E., Stern N. Aldosterone increase oxidative stress in differentiated but not in undifferentiated 3T3-L1 adipocytes via activation of mineralocorticoid and glucocorticoid receptors 2012, International Congress of Endocrinology, Florence.
100. McCarty M.F. ACE inhibition may decrease diabetes risk by boosting the impact of bradykinin on adipocytes. Med Hypotheses 2003, 60:779-783.
101. Waeber B., Brunner H.R. Cardiovascular hypertrophy: role of angiotensin II and bradykinin. J Cardiovasc Pharmacol 1996, 27(Suppl 2):S36-S40.
102. Isami S., Kishikawa H., Araki E., Uehara M., Kaneko K., Shirotani T., et al. Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway. Diabetologia 1996, 39:412-420.
103. Beard K.M., Lu H., Ho K., Fantus I.G. Bradykinin augments insulin-stimulated glucose transport in rat adipocytes via endothelial nitric oxide synthase-mediated inhibition of Jun NH2-terminal kinase. Diabetes 2006, 55:2678-2687.
104. Imayama I., Ichiki T., Inanaga K., Ohtsubo H., Fukuyama K., Ono H., et al. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res 2006, 72:184-190.
105. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43:993-1002.
106. Schupp M., Janke J., Clasen R., Unger T., Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109:2054-2057.
107. Kintscher U., Law R.E. PPARgamma-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab 2005, 288:E287-E291.
108. Medina-Gomez G., Gray S., Vidal-Puig A. Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1). Public Health Nutr 2007, 10:1132-1137.
109. Fain J.N., Madan A.K., Hiler M.L., Cheema P., Bahouth S.W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145:2273-2282.
110. Funakoshi Y., Ichiki T., Shimokawa H., Egashira K., Takeda K., Kaibuchi K., et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 2001, 38:100-104.
111. Asamizu S., Urakaze M., Kobashi C., Ishiki M., Norel Din A.K., Fujisaka S., et al. Angiotensin II enhances the increase in monocyte chemoattractant protein-1 production induced by tumor necrosis factor-{alpha} from 3T3-L1 preadipocytes. J Endocrinol 2009, 202:199-205.
112. Kurata A., Nishizawa H., Kihara S., Maeda N., Sonoda M., Okada T., et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006, 70:1717-1724.
113. Hung W.W., Hsieh T.J., Lin T., Chou P.C., Hsiao P.J., Lin K.D., et al. Blockade of the renin-angiotensin system ameliorates apelin production in 3T3-L1 adipocytes. Cardiovasc Drugs Ther 2011, 25:3-12.
114. Benter I.F., Yousif M.H., Anim J.T., Cojocel C., Diz D.I. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol 2006, 290:H684-H691.
115. Santos S.H., Braga J.F., Mario E.G., Porto L.C., Rodrigues-Machado Mda G., Murari A., et al. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arterioscler Thromb Vasc Biol 2010, 30:953-961.
116. Cornelius P., MacDougald O.A., Lane M.D. Regulation of adipocyte development. Annu Rev Nutr 1994, 14:99-129.
117. Masson O., Prebois C., Derocq D., Meulle A., Dray C., Daviaud D., et al. Cathepsin-D, a key protease in breast cancer, is up-regulated in obese mouse and human adipose tissue, and controls adipogenesis. PLoS One 2011, 6:e16452.
118. Vassaux G., Gaillard D., Ailhaud G., Negrel R. Prostacyclin is a specific effector of adipose cell differentiation. Its dual role as a cAMP- and Ca(2+)-elevating agent. J Biol Chem 1992, 267:11092-11097.
119. Darimont C., Vassaux G., Gaillard D., Ailhaud G., Negrel R. In situ microdialysis of prostaglandins in adipose tissue: stimulation of prostacyclin release by angiotensin II. Int J Obes 1994, 18:783-788.
120. Hauner H. Adipocytes as a source and target of hormones: recent developments in adipose tissue physiology. Int Mon on EP & WC. 1996;5.
121. Saint-Marc P., Kozak L.P., Ailhaud G., Darimont C., Negrel R. Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. Endocrinology 2001, 142:487-492.
122. Fuentes P., Acuna M.J., Cifuentes M., Rojas C.V. The anti-adipogenic effect of angiotensin II on human preadipose cells involves ERK1,2 activation and PPARG phosphorylation. J Endocrinol 2010, 206:75-83.
123. Aubert J., Ailhaud G., Negrel R. Evidence for a novel regulatory pathway activated by (carba)prostacyclin in preadipose and adipose cells. FEBS Lett 1996, 397:117-121.
124. Massiera F., Saint-Marc P., Seydoux J., Murata T., Kobayashi T., Narumiya S., et al. Arachidonic acid and prostacyclin signaling promote adipose tissue development: a human health concern?. J Lipid Res 2003, 44:271-279.
125. Negrel R. Prostacyclin as a critical prostanoid in adipogenesis. Prostaglandins Leukot Essent Fatty Acids 1999, 60:383-386.
126. Darimont C., Vassaux G., Ailhaud G., Negrel R. Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II. Endocrinology 1994, 135:2030-2036.
127. Iwai M., Tomono Y., Inaba S., Kanno H., Senba I., Mogi M., et al. AT2 receptor deficiency attenuates adipocyte differentiation and decreases adipocyte number in atherosclerotic mice. Am J Hypertens 2009, 22:784-791.
128. Brucher R., Cifuentes M., Acuna M.J., Albala C., Rojas C.V. Larger anti-adipogenic effect of angiotensin II on omental preadipose cells of obese humans. Obesity (Silver Spring) 2007, 15:1643-1646.
129. Strazzullo P., Galletti F. Impact of the renin-angiotensin system on lipid and carbohydrate metabolism. Curr Opin Nephrol Hypertens 2004, 13:325-332.
130. Ailhaud G., Teboul M., Massiera F. Angiotensinogen, adipocyte differentiation and fat mass enlargement. Curr Opin Clin Nutr Metab Care 2002, 5:385-389.
131. Tomono Y., Iwai M., Inaba S., Mogi M., Horiuchi M. Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens 2008, 21:206-212.
132. Zorad S., Dou J.T., Benicky J., Hutanu D., Tybitanclova K., Zhou J., et al. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 2006, 552:112-122.
133. Cassis L.A., Fettinger M.J., Roe A.L., Shenoy U.R., Howard G. Characterization and regulation of angiotensin II receptors in rat adipose tissue. Angiotensin receptors in adipose tissue. Adv Exp Med Biol 1996, 396:39-47.
134. Kalupahana N.S., Massiera F., Quignard-Boulange A., Ailhaud G., Voy B.H., Wasserman D.H., et al. Overproduction of angiotensinogen from adipose tissue induces adipose inflammation, glucose intolerance, and insulin resistance. Obesity (Silver Spring) 2012, 20:48-56.
135. Yvan-Charvet L., Massiera F., Lamande N., Ailhaud G., Teboul M., Moustaid-Moussa N., et al. Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinology 2009, 150:1421-1428.
136. Carroll W.X., Kalupahana N.S., Booker S.L., Siriwardhana N., Lemieux M., Saxton A.M., et al. Angiotensinogen gene silencing reduces markers of lipid accumulation and inflammation in cultured adipocytes. Front Endocrinol 2013, 4:10.
137. Jurewicz M., McDermott D.H., Sechler J.M., Tinckam K., Takakura A., Carpenter C.B., et al. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 2007, 18:1093-1102.
138. Skurk T., van Harmelen V., Hauner H. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB. Arterioscler Thromb Vasc Biol 2004, 24:1199-1203.
139. Tsuchiya K., Yoshimoto T., Hirono Y., Tateno T., Sugiyama T., Hirata Y. Angiotensin II induces monocyte chemoattractant protein-1 expression via a nuclear factor-kappaB-dependent pathway in rat preadipocytes. Am J Physiol Endocrinol Metab 2006, 291:E771-E778.
140. Fujisaka S., Usui I., Kanatani Y., Ikutani M., Takasaki I., Tsuneyama K., et al. Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice. Endocrinology 2011, 152:1789-1799.
141. Cole B.K., Keller S.R., Wu R., Carter J.D., Nadler J.L., Nunemaker C.S. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension 2010, 55:715-721.
142. Hakim J. [Reactive oxygen species and inflammation]. Comptes rendus des seances de la Societe de biologie et de ses filiales. 1993;187:286-95.
143. Chabrashvili T., Kitiyakara C., Blau J., Karber A., Aslam S., Welch W.J., et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 2003, 285:R117-R124.
144. Hussein O., Shneider J., Rosenblat M., Aviram M. Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients. J Cardiovasc Pharmacol 2002, 40:28-34.
145. Mervaala E.M., Cheng Z.J., Tikkanen I., Lapatto R., Nurminen K., Vapaatalo H., et al. Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension 2001, 37:414-418.
146. Elliott S.S., Keim N.L., Stern J.S., Teff K., Havel P.J. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 2002, 76:911-922.
147. Chou C.L., Lai Y.H., Lin T.Y., Lee T.J., Fang T.C. Aliskiren prevents and ameliorates metabolic syndrome in fructose-fed rats. Arch Med Sci 2011, 7:882-888.
148. Rafiq K., Hitomi H., Nakano D., Ichihara A., Nishiyama A. Possible involvement of the (pro)renin receptor-dependent system in the development of insulin resistance. Front Biosci (Schol Ed) 2011, 3:1478-1485.
149. Ishibashi S. The vascular renin-angiotensin system as a possible source of vascular inflammation in fructose-fed rats. Hypertens Res 2007, 30:375-376.
150. Iyer S.N., Katovich M.J., Raizada M.K. Changes in angiotensin AT1 receptor density during hypertension in fructose-fed rats. Adv Exp Med Biol 1996, 396:49-58.
151. Nyby M.D., Abedi K., Smutko V., Eslami P., Tuck M.L. Vascular angiotensin type 1 receptor expression is associated with vascular dysfunction, oxidative stress and inflammation in fructose-fed rats. Hypertens Res 2007, 30:451-457.
152. Shinozaki K., Ayajiki K., Nishio Y., Sugaya T., Kashiwagi A., Okamura T. Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension 2004, 43:255-262.
153. Pachori A.S., Huentelman M.J., Francis S.C., Gelband C.H., Katovich M.J., Raizada M.K. The future of hypertension therapy: sense, antisense, or nonsense?. Hypertension 2001, 37:357-364.
154. Giani J.F., Mayer M.A., Munoz M.C., Silberman E.A., Hocht C., Taira C.A., et al. Chronic infusion of angiotensin-(1-7) improves insulin resistance and hypertension induced by a high-fructose diet in rats. Am J Physiol Endocrinol Metab 2009, 296:E262-E271.
155. Giacchetti G., Sechi L.A., Griffin C.A., Don B.R., Mantero F., Schambelan M. The tissue renin-angiotensin system in rats with fructose-induced hypertension: overexpression of type 1 angiotensin II receptor in adipose tissue. J Hypertens 2000, 18:695-702.
156. Furuhashi M., Ura N., Takizawa H., Yoshida D., Moniwa N., Murakami H., et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004, 22:1977-1982.
157. Freitas R.R., Lopes K.L., Carillo B.A., Bergamaschi C.T., Carmona A.K., Casarini D.E., et al. Sympathetic and renin-angiotensin systems contribute to increased blood pressure in sucrose-fed rats. Am J Hypertens 2007, 20:692-698.
158. Noriega-Lopez L., Tovar A.R., Gonzalez-Granillo M., Hernandez-Pando R., Escalante B., Santillan-Doherty P., et al. Pancreatic insulin secretion in rats fed a soy protein high fat diet depends on the interaction between the amino acid pattern and isoflavones. J Biol Chem 2007, 282:20657-20666.
159. Palacios-Gonzalez B., Torres N., Tovar A.R. Genistein stimulates AMPK phosphorylation and expression of genes involved in fatty acid oxidation in skeletal muscle. FASEB J 2011, 25:772.
160. Tovar A.R., Torre-Villalvazo I., Ochoa M., Elias A.L., Ortiz V., Aguilar-Salinas C.A., et al. Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats. J Lipid Res 2005, 46:1823-1832.
161. Frigolet M.E., Torres N., Uribe-Figueroa L., Rangel C., Jimenez-Sanchez G., Tovar A.R. White adipose tissue genome wide-expression profiling and adipocyte metabolic functions after soy protein consumption in rats. J Nutr Biochem 2011, 22:118-129.
162. Vasdev S., Stuckless J. Antihypertensive effects of dietary protein and its mechanism. Int J Angiol 2010, 19:e7-e20.
163. Frigolet M.E., Torres N., Tovar A.R. Soya protein attenuates abnormalities of the renin-angiotensin system in adipose tissue from obese rats. Br J Nutr 2012, 107:36-44.
164. Lo W.M., Li-Chan E.C. Angiotensin I converting enzyme inhibitory peptides from in vitro pepsin-pancreatin digestion of soy protein. J Agric Food Chem 2005, 53:3369-3376.
165. Yang H.Y., Yang S.C., Chen S.T., Chen J.R. Soy protein hydrolysate ameliorates cardiovascular remodeling in rats with L-NAME-induced hypertension. J Nutr Biochem 2008, 19:833-839.
166. Xu Y.Y., Yang C., Li S.N. Effects of genistein on angiotensin-converting enzyme in rats. Life Sci 2006, 79:828-837.
167. Ma L.J., Corsa B.A., Zhou J., Yang H., Li H., Tang Y.W., et al. Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Am J Physiol Renal Physiol 2011, 300:F1203-F1213.
168. Massiera F., Seydoux J., Geloen A., Quignard-Boulange A., Turban S., Saint-Marc P., et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 2001, 142:5220-5225.
169. Boustany C.M., Bharadwaj K., Daugherty A., Brown D.R., Randall D.C., Cassis L.A. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 2004, 287:R943-R949.
170. Gupte M., Boustany-Kari C.M., Bharadwaj K., Police S., Thatcher S., Gong M.C., et al. ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol 2008, 295:R781-R788.
171. Sun X., Pan H., Tan H., Yu Y. High free fatty acids level related with cardiac dysfunction in obese rats. Diabetes Res Clin Pract 2012, 95:251-259.
172. Tian Y.Q., Li S.S., Su X.D., Zhang G.Z., Zhao J.J., Li G.W., et al. Effects of pioglitazone on high-fat-diet-induced ventricular remodeling and dysfunction in rats. J Cardiovasc Pharmacol Ther 2012, 17:223-228.
173. Boustany C.M., Brown D.R., Randall D.C., Cassis L.A. AT1-receptor antagonism reverses the blood pressure elevation associated with diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2005, 289:R181-R186.
174. de las Heras N., Martin-Fernandez B., Miana M., Ballesteros S., Oubina M.P., Lopez-Farre A.J., et al. The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptin-adiponectin imbalance. J Hypertens Suppl 2009, 27:S37-S41.
175. Stucchi P., Cano V., Ruiz-Gayo M., Fernandez-Alfonso M.S. Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. Br J Pharmacol 2009, 158:771-778.
176. Weisinger R.S., Stanley T.K., Begg D.P., Weisinger H.S., Spark K.J., Jois M. Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. Physiol Behav 2009, 98:192-197.
177. Chung S., Park C.W., Shin S.J., Lim J.H., Chung H.W., Youn D.Y., et al. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats. Nephrol Dial Transplant 2010, 25:389-399.
178. Li X., Ren H., Xu Z.R., Liu Y.J., Yang X.P., Liu J.Q. Prevalence and risk factors of prolonged QTc interval among Chinese patients with type 2 diabetes. Exp Diabetes Res 2012, 2012:234084.
179. Yuan L., Li X., Li J., Li H.L., Cheng S.S. Effects of renin-angiotensin system blockade on the islet morphology and function in rats with long-term high-fat diet. Acta Diabetol 2013, 50:479-488.
180. Vinh A., Widdop R.E., Drummond G.R., Gaspari T.A. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res 2008, 77:178-187.
181. Northcott C.A., Fink G.D., Garver H., Haywood J.R., Laimon-Thomson E.L., McClain J.L., et al. The development of hypertension and hyperaldosteronism in a rodent model of life-long obesity. Endocrinology 2012, 153:1764-1773.
182. Takeda M., Yamamoto K., Takemura Y., Takeshita H., Hongyo K., Kawai T., et al. Loss of ACE2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice. Diabetes 2013, 62:223-233.
183. Kurukulasuriya L.R., Stas S., Lastra G., Manrique C., Sowers J.R. Hypertension in obesity. Endocrinol Metab Clin North Am 2008, 37:647-662. ix.
184. Engler M.M., Engler M.B., Erickson S.K., Paul S.M. Dietary gamma-linolenic acid lowers blood pressure and alters aortic reactivity and cholesterol metabolism in hypertension. J Hypertens 1992, 10:1197-1204.
185. Engler M.M., Schambelan M., Engler M.B., Ball D.L., Goodfriend T.L. Effects of dietary gamma-linolenic acid on blood pressure and adrenal angiotensin receptors in hypertensive rats. Proc Soc Exp Biol Med 1998, 218:234-237.
186. Jayasooriya A.P., Begg D.P., Chen N., Mathai M.L., Sinclair A.J., Wilkinson-Berka J., et al. Omega-3 polyunsaturated fatty acid supplementation reduces hypertension in TGR(mRen-2)27 rats. Prostaglandins Leukot Essent Fatty Acids 2008, 78:67-72.
187. Wyrwoll C.S., Mark P.J., Waddell B.J. Developmental programming of renal glucocorticoid sensitivity and the renin-angiotensin system. Hypertension 2007, 50:579-584.
188. DeClercq V., Taylor C.G., Zahradka P. Isomer-specific effects of conjugated linoleic acid on blood pressure, adipocyte size and function. Br J Nutr 2012, 107:1413-1421.
189. Ferraro P.M., Ferraccioli G.F., Gambaro G., Fulignati P., Costanzi S. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol Dial Transplant 2009, 24:156-160.
190. Pinterova L., Zelezna B., Fickova M., Macho L., Krizanova O., Jezova D., et al. Elevated AT1 receptor protein but lower angiotensin II-binding in adipose tissue of rats with monosodium glutamate-induced obesity. Horm Metab Res 2001, 33:708-712.
191. Samuel P., Ali Q., Sabuhi R., Wu Y., Hussain T. High Na intake increases renal angiotensin II levels and reduces expression of the ACE2-AT(2)R-MasR axis in obese Zucker rats. Am J Physiol Renal Physiol 2012, 303:F412-F419.
192. Perricone N.V., Bagchi D., Echard B., Preuss H.G. Long-term metabolic effects of different doses of niacin-bound chromium on Sprague-Dawley rats. Mol Cell Biochem 2010, 338:91-103.
193. Huang W.Y., Davidge S.T., Wu J. Bioactive natural constituents from food sources-potential use in hypertension prevention and treatment. Crit Rev Food Sci Nutr 2013, 53:615-630.
194. Steckelings U.M., Rompe F., Kaschina E., Unger T. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam Clin Pharmacol 2009, 23:693-703.
195. Kalupahana N.S., Moustaid-Moussa N. The adipose tissue renin-angiotensin system and metabolic disorders: a review of molecular mechanisms. Crit Rev Biochem Mol Biol 2012, 47:379-390.
196. Kramer H., Wu X., Kan D., Luke A., Zhu X., Adeyemo A., et al. Angiotensin-converting enzyme gene polymorphisms and obesity: an examination of three black populations. Obes Res 2005, 13:823-828.
197. Strazzullo P., Iacone R., Iacoviello L., Russo O., Barba G., Russo P., et al. Genetic variation in the renin-angiotensin system and abdominal adiposity in men: the Olivetti Prospective Heart Study. Ann Intern Med 2003, 138:17-23.
198. Engeli S., Bohnke J., Gorzelniak K., Janke J., Schling P., Bader M., et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005, 45:356-362.
199. Campbell D.J., Kladis A., Valentijn A.J. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1995, 26:233-240.
200. Setoguchi Y., Ohnuki T., Rashid M., Nakamura T., Hattori K., Nagatomo T., et al. Effects of chronic administration of sarpogrelate on systolic blood pressure of spontaneously hypertensive rats: comparison with quinapril. Pharmacology 2002, 64:71-75.
201. Yiannikouris F., Gupte M., Putnam K., Thatcher S., Charnigo R., Rateri D.L., et al. Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice. Hypertension 2012, 60:1524-1530.
202. Hall J.E., Brands M.W., Henegar J.R. Mechanisms of hypertension and kidney disease in obesity. Ann N Y Acad Sci 1999, 892:91-107.
203. de Paula R.B., da Silva A.A., Hall J.E. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004, 43:41-47.
204. Reisin E., Weir M.R., Falkner B., Hutchinson H.G., Anzalone D.A., Tuck M.L. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997, 30:140-145.
205. Vermes E., Ducharme A., Bourassa M.G., Lessard M., White M., Tardif J.C. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003, 107:1291-1296.
206. Nagel J.M., Tietz A.B., Goke B., Parhofer K.G. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 2006, 55:1149-1154.
207. Steen M.S., Foianini K.R., Youngblood E.B., Kinnick T.R., Jacob S., Henriksen E.J. Interactions of exercise training and ACE inhibition on insulin action in obese Zucker rats. J Appl Physiol 1999, 86:2044-2051.
208. Frederich R.C., Kahn B.B., Peach M.J., Flier J.S. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992, 19:339-344.
209. Hainault I., Nebout G., Turban S., Ardouin B., Ferre P., Quignard-Boulange A. Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat. Am J Physiol Endocrinol Metab 2002, 282:E59-E66.
210. Lu H., Boustany-Kari C.M., Daugherty A., Cassis L.A. Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab 2007, 292:E1280-E1287.
211. Skurk T., Lee Y.M., Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 2001, 37:1336-1340.
212. Skurk T., van Harmelen V., Blum W.F., Hauner H. Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2-dependent pathway. Obes Res 2005, 13:969-973.
213. Kim S., Whelan J., Claycombe K., Reath D.B., Moustaid-Moussa N. Angiotensin II increases leptin secretion by 3T3-L1 and human adipocytes via a prostaglandin-independent mechanism. J Nutr 2002, 132:1135-1140.
214. Dunbar J.C., Hu Y., Lu H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes 1997, 46:2040-2043.
215. Shek E.W., Brands M.W., Hall J.E. Chronic leptin infusion increases arterial pressure. Hypertension 1998, 31:409-414.
216. Chantemele EJ Belin, Mintz J.D., Rainey W.E., Stepp D.W. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertension 2011, 58:271-279.
217. Quehenberger P., Exner M., Sunder-Plassmann R., Ruzicka K., Bieglmayer C., Endler G., et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 2002, 90:711-718.
218. Adamczak M., Wiecek A., Funahashi T., Chudek J., Kokot F., Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003, 16:72-75.
219. Francischetti E.A., Celoria B.M., Duarte S.F., da Silva E.G., Santos I.J., Cabello P.H., et al. Hypoadiponectinemia is associated with blood pressure increase in obese insulin-resistant individuals. Metabolism 2007, 56:1464-1469.
220. Iwashima Y., Katsuya T., Ishikawa K., Ouchi N., Ohishi M., Sugimoto K., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004, 43:1318-1323.
221. Clasen R., Schupp M., Foryst-Ludwig A., Sprang C., Clemenz M., Krikov M., et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005, 46:137-143.
222. Chen H., Montagnani M., Funahashi T., Shimomura I., Quon M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003, 278:45021-45026.
223. Motoshima H., Wu X., Mahadev K., Goldstein B.J. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004, 315:264-271.
224. Grekin R.J., Vollmer A.P., Sider R.S. Pressor effects of portal venous oleate infusion. A proposed mechanism for obesity hypertension. Hypertension 1995, 26:193-198.
225. Boden G., Shulman G.I. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002, 32(Suppl 3):14-23.
226. Safonova I., Aubert J., Negrel R., Ailhaud G. Regulation by fatty acids of angiotensinogen gene expression in preadipose cells. Biochem J 1997, 322(Pt 1):235-239.
227. Sarafidis P.A., Bakris G.L. Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance?. J Hum Hypertens 2007, 21:12-19.
228. Bujalska I.J., Kumar S., Stewart P.M. Does central obesity reflect "Cushing's disease of the omentum"?. Lancet 1997, 349:1210-1213.
229. Ferrari P., Lovati E., Frey F.J. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. J Hypertens 2000, 18:241-248.
230. Masuzaki H., Yamamoto H., Kenyon C.J., Elmquist J.K., Morton N.M., Paterson J.M., et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003, 112:83-90.